Donepezil PCD Pharma Franchise Company
Cafoli Lifecare offers a Donepezil range of 4 tablet formulations, manufactured in WHO-GMP certified facilities. Distributors serving neurology, psychiatry and geriatric prescribers can secure district-wise monopoly franchise rights for this anti-dementia molecule with full promotional support.
What is Donepezil?
Donepezil is a centrally acting acetylcholinesterase inhibitor. By slowing the breakdown of acetylcholine it improves cholinergic transmission in the brain, helping maintain memory and cognitive function in dementia. Reference: PubChem - Donepezil.
Available Forms
The Cafoli Donepezil portfolio is offered as oral Tablets in the commonly prescribed strengths (5mg, 10mg), including memantine combinations. Contact us for current pack presentations and combinations.
Therapeutic Applications
Donepezil is prescribed for mild-to-moderate and moderate-to-severe Alzheimer disease and other dementias to improve or stabilise cognition and daily functioning. Prescribers include neurologists, psychiatrists and geriatric physicians.
Why Donepezil is a High-Potential Molecule for Distributors
India ageing population is driving a steady rise in dementia, and donepezil is the first-line, long-term treatment prescribed continuously for years. As a chronic, specialist-initiated therapy - often as donepezil-memantine combinations - it gives distributors dependable, high-retention refill volume in a growing neuro-geriatric segment with limited competition.
Why Choose Cafoli Lifecare
Cafoli Lifecare offers monopoly franchise rights, WHO-GMP certified manufacturing, DCGI-approved formulations, a network of 1000+ franchise partners across India, and free promotional inputs.
References
- PubChem: Donepezil
- MedlinePlus: Donepezil
- PubMed: donepezil in Alzheimer dementia
Our formulations of Donepezil find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: